During these last 20 years, there has been no lack of threats to the company’s well-being. Firstly, increased regulatory and technical constraints have resulted in strong inflation of the costs of production and of clinical development, creating new conditions that are more in line with the investment capabilities of major pharmaceutical groups than with those of an average-sized company. The Group’s recent history is marked by internal and external events with serious consequences:…

The choice of daily pathologies In response to the constraints weighing on the health industries, the directors of INNOTHERA decided to concentrate on daily pathologies. These diseases that are often symptomatic, chronic, but without major or lethal risks do not lend themselves to sophisticated, costly treatments that involve significant side effects. This segment of the market is the one most often neglected by the research departments of the major laboratories. The treatment of these daily…

The first export department at INNOTHERA was created in 1974. Exporting has been a part of the life of the Group for more than 30 years. At first oriented exclusively toward French-speaking countries (the Maghreb and Sub-Saharan Africa), the Group now exports to more than 100 countries with variable levels of penetration from one region of the globe to another. Finally, a new program of extension is under way, following the decision to establish a presence in the United States. The export…

Among the innovations issued from INNOTHERA research, three products illustrate the company’s ongoing concern with providing new therapeutic solutions suited to patients’ needs for relieving their daily suffering. Diovenor 600® - One time per day Launched in 1995, Diovenor 600® one per day is the first veinotonic to offer simplified dosage, facilitating observance and patient comfort. With a dosage of one tablet per day instead of several tablets in two daily doses, the…

The small number of clinical studies available, coupled with the difficulty of modeling the venous system, led INNOTHERA to look for additional methods of acquisition of knowledge and evaluation of the effects of venous compression. In 1995, the Laboratory of Biophysics was founded through the efforts of Arnaud Gobet. Its purpose was to develop and modernize Elastic Venous Compression and make it a full-fledged form of medical therapeutics, fully adapted to patient needs. This work is based on a…

The company’s enduring adaptability, spirit of innovation, and constant investment in research and development have allowed INNOTHERA to overcome the difficulties that have marked its history. Now the second-ranking operator on the venous-compression market in France, INNOTHERA is making a success of this new transformation. The 10% share of sales on the international level accounted for by these devices holds serious promise for the years ahead.

During these years of accelerated transformation, INNOTHERA’s main strength was to promote a model of growth whose functioning takes into account the difficulties encountered on the markets. Regulatory difficulties: The increasingly stringent regulations make the crucial phase of product licensing in each country longer, complex, and more and more costly, and very significantly increase production costs in a context where prices are frozen. Added to all these difficulties is the industrial…

« We are ambitious and modest, working over the long term with patience, determination, and good sense for the continuous improvement of the treatment of daily pathologies in the world.We rely first and foremost on our energy, our individual and collective commitment, founded on the assimilation of many cultures and disciplines, in a spirit of trust and mutual aid. » Arnaud Gobet, Chief Executive Officer of INNOTHERA

In 1985, INNOTHERA’s annual sales amounted to approximately 200 MF (30 M€),, exclusively of medicines, of which 75% was in France and 25% at export; the company ranked 17th among independent French pharmaceutical companies. In 2007, INNOTHERA’s sales totaled 116 M€, of which 57% was international sales, divided into two activities: • medicines: 2/3 of the total business activity, of which 80% was exports, • medical textiles (venous compression bandages and…

Innothera, an industrial group created in the late 1920s by René Chantereau, a pharmacist, and developed by Bernard Gobet, has been under the direction of Arnaud Gobet, the founder’s grandson, since 1986. For more than eighty years this family company, from generation to generation, has handed down the values that give it life and are evident at all the stages of its history. These profoundly humanistic values are the basis of the Laboratory’s identity. Their universality has…

INNOTHERA employs 1000 persons in which 600 in France, both at its headquarters and its two main regional sites: The Loir-et-Cher for medicines The first phase of decentralization of the company began in 1973 from the Group’s historical headquarters in Arcueil (Val de Marne). The plant in Chouzysur- Cisse (Loir-et-Cher) was given the task of bringing together and developing pharmaceutics production. The search for greater efficiency led the Group to build a new pharmaceutical development…